Regenxbio Inc. (RGNX) Shares Up 5.1%
Regenxbio Inc. (NASDAQ:RGNX)’s share price shot up 5.1% during mid-day trading on Wednesday . The company traded as high as $8.35 and last traded at $8.27, with a volume of 87,213 shares traded. The stock had previously closed at $7.87.
A number of brokerages recently issued reports on RGNX. Zacks Investment Research cut Regenxbio from a “buy” rating to a “hold” rating in a report on Thursday, July 7th. Piper Jaffray Cos. restated a “buy” rating and issued a $33.00 target price on shares of Regenxbio in a report on Tuesday, July 5th. Chardan Capital restated a “buy” rating on shares of Regenxbio in a report on Tuesday, May 10th. Finally, Morgan Stanley lifted their target price on Regenxbio from $34.00 to $36.00 in a report on Friday, April 8th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $28.35.
Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.01.
In related news, insider Fmr Llc sold 6,046 shares of the business’s stock in a transaction dated Tuesday, May 3rd. The stock was sold at an average price of $10.76, for a total transaction of $65,054.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.